- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05374252
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
May 10, 2022 updated by: Sixth Affiliated Hospital, Sun Yat-sen University
A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma
This is a phase III, multi-center, double-blind randomized controlled trial assessing the efficacy and safety of concurrent mitomycin C/5-Fu chemotherapy and long-course IMRT combined with PD-1 antibody Sintilimab for locally advanced anal canal squamous carcinoma patients, by comparing an experiment group (traditional chemoradiotherapy with PD-1 antibody Sintilimab) with a control group (traditional treatment without Sintilimab).
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
102
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiang-bo Wan, PhD
- Phone Number: +86-13826017157
- Email: wanxbo@mail.sysu.edu.cn
Study Contact Backup
- Name: Fang He, MD
- Phone Number: +86-20-85655905
- Email: hefang23@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- Recruiting
- The Sixth Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Xiang-bo Wan, PhD
- Phone Number: +86-13826017157
- Email: wanxbo@mail.sysu.edu.cn
-
Contact:
- Fang He, MD
- Phone Number: +86-20-85655905
- Email: hefang23@mail.sysu.edu.cn
-
Principal Investigator:
- Xiang-bo Wan, PhD
-
Sub-Investigator:
- Fang He, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histology identified anal canal squamous carcinoma,
- Aged 18 to 75,
- Clinical staging III, Eastern Cooperative Oncology Group 0-2 score,
- The Staging method: All patients undergoing rectal anus palpation, high resolution MRI and chest-abdominal enhanced CT, clinical data should be re-evaluated and inclusive by center evaluation group when there is contradictory staging, distant metastasis were excluded by chest-abdominal enhanced CT and pelvic enhanced MRI,
- No previous anal canal surgery or anal tumor resection (except for biopsy),
- No previous chemotherapy or pelvic radiotherapy history,
- No biopharmaceutical treatment history (such as monoclonal antibody), immunotherapy (such as anti PD-1antibody, anti PD-L1 antibody, anti PD-L2 antibody or anti CTLA-4), or other research drug treatment in the previous 5 years,
- Adequate bone marrow, liver, and kidney function,
- Clinical complete response (cCR) (Chest, abdominal and pelvic enhanced CT or pelvic enhanced MRI or PET/CT),
- Informed consent assigned, Final inclusion criteria,
- Non-pregnant or breast-feeding women,
- No other malignant disease within 5 years before diagnosis of anal cancer squamous carcinoma (except endocervical cancer in situ or skin basal cell carcinoma which had been cured); no other malignant disease beside anal cancer squamous carcinoma,
- No other serious disease leading to shortened survival.
Exclusion Criteria:
- Diagnosed as stage I-II and well differentiated squamous cell carcinoma,
- Distant metastasis,
- Received radiation therapy in abdominal or pelvic regions,
- Pregnant, lactating woman patient or fertile but lacks adequate contraceptives,
- Arrhythmia need anti-arrhythmia treatment (except β-blocking agent or Digoxin), symptomatic coronary heart disease or myocardial ischemia (myocardial infarction within 6 months) or congestive heart-failure (CHF) > New York Heart Association grade II,
- Severe hypertension not well controlled by drugs,
- Active phase of chronic hepatitis B or hepatitis C (high copies of virus DNA),
- Patients with active tuberculosis (TB) are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year before screening,
- Other active clinical severe infection (NCI-CTCAE (version 4.0) ),
- Dyscrasia, organ dysfunction,
- Known or suspicious allergy to any research-related drugs,
- Epilepsy needs treatments (Steroid or anti-epilepsy therapy),
- Other malignant tumor history within 5 years,
- Drug abuse and medical, psychological, or social factors that may interfere with patients' participation in the study or affect the evaluation of the study,
- Patients have any active autoimmune diseases or a history of autoimmune diseases (including but not restricted: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and decreased thyroid function; patients with vitiligo or with complete remission of asthma in childhood and without any intervention in adulthood may be included; patients with asthma requiring bronchodilators intervention are not included,
- Any anti-infection vaccine 4 weeks before inclusion,
- Long-term exposure to immune-suppressor, combination of systemic or topical use of corticosteroids (dose>10mg/day prednisolone or equivalent hormone),
- Any unstable state might endanger the patients' safety and compliance,
- Refuses to sign informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group
Concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil, and IMRT, followed by adjuvant sintilimab
|
Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
Other Names:
|
Active Comparator: Control Group
Concurrent mytomicin C and 5-fluorouracil combined with IMRT
|
Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cCR rate
Time Frame: 6 months after treatment
|
cCR rate 6 months after treatment
|
6 months after treatment
|
Progression free survival
Time Frame: from the end of treatment to 3 years after treatment
|
progression free survival
|
from the end of treatment to 3 years after treatment
|
Overall survival
Time Frame: from the end of treatment to 3 years after treatment
|
overall survival
|
from the end of treatment to 3 years after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cCR rate
Time Frame: 3 months after treatment
|
cCR rate 3 months after treatment
|
3 months after treatment
|
Acute toxicities
Time Frame: from the start of treatment to 3 months after treatment
|
acute toxicities according to the NCI CTCAE (version 4.0)
|
from the start of treatment to 3 months after treatment
|
The rate of late toxicity according to the RTOG/EORTC scale
Time Frame: 3 years
|
The rate of late toxicity according to the RTOG/EORTC scale
|
3 years
|
Colostomy rate
Time Frame: 2 year
|
colostomy rate
|
2 year
|
Local recurrence rate
Time Frame: from the end of treatment to 3 years after treatment
|
local recurrence rate
|
from the end of treatment to 3 years after treatment
|
Distant metastasis rate
Time Frame: from the end of treatment to 3 years after treatment
|
distant metastasis rate
|
from the end of treatment to 3 years after treatment
|
Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events
Time Frame: 1 year
|
Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiang-bo Wan, PhD, Sun Yat-sen University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996 Oct 19;348(9034):1049-54.
- Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010 Mar 30;102(7):1123-8. doi: 10.1038/sj.bjc.6605605. Epub 2010 Mar 16.
- James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013 May;14(6):516-24. doi: 10.1016/S1470-2045(13)70086-X. Epub 2013 Apr 9.
- Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 1;28(34):5061-6. doi: 10.1200/JCO.2010.29.1351. Epub 2010 Oct 18.
- Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029.
- Shahjehan F, Kamatham S, Ritter A, Kasi PM. Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer. Clin Case Rep. 2019 Aug 6;7(9):1729-1734. doi: 10.1002/ccr3.2333. eCollection 2019 Sep.
- Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997 May;15(5):2040-9.
- Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):638-45. doi: 10.1016/j.ijrobp.2013.07.035. Epub 2013 Sep 10.
- Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974 May-Jun;17(3):354-6. doi: 10.1007/BF02586980. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2022
Primary Completion (Anticipated)
May 31, 2025
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
May 10, 2022
First Submitted That Met QC Criteria
May 10, 2022
First Posted (Actual)
May 16, 2022
Study Record Updates
Last Update Posted (Actual)
May 16, 2022
Last Update Submitted That Met QC Criteria
May 10, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Neoplasms, Squamous Cell
- Rectal Neoplasms
- Anus Diseases
- Carcinoma
- Carcinoma, Squamous Cell
- Anus Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immune Checkpoint Inhibitors
Other Study ID Numbers
- E2021144
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Canal Cancer
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingAnal Squamous Cell Carcinoma | Anal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Canal Carcinoma | Recurrent Anal Canal Carcinoma | Stage IIIB Anal Canal Cancer | Stage IV Anal Canal CancerUnited States
-
Sun Yat-sen UniversityEnrolling by invitationAnal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage I | Anal Canal Cancer Stage II | Anal Canal Cancer Stage IIIChina
-
National Cancer Institute (NCI)Active, not recruitingAnal Canal Squamous Cell Carcinoma | Metastatic Anal Canal Carcinoma | Stage IV Anal Canal Cancer AJCC v6 and v7United States, Canada
-
AHS Cancer Control AlbertaUnknown
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Anal Canal Squamous Cell Carcinoma | Anal Margin Squamous Cell Carcinoma | Stage I Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
-
Institut Cancerologie de l'OuestCompletedCervical Cancer | Prostate Cancer | Anal Canal CancersFrance
-
Centre Hospitalier Universitaire de BesanconCompletedMetastatic Anal Canal Cancer | Human PapillomavirusFrance
-
Centre Francois BaclesseAccuray IncorporatedActive, not recruitingLocally Advanced Anal Canal CancerFrance
-
Mansoura UniversityCompletedHypertensive Anal CanalEgypt
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
Clinical Trials on PD-1 inhibitor
-
Adanate, IncRecruiting
-
Istari Oncology, Inc.Active, not recruiting
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Dong WangNot yet recruiting
-
Shanghai Chest HospitalRecruitingNon Small Cell Lung CancerChina
-
Canadian Cancer Trials GroupMelanoma and Skin Cancer Trials LimitedRecruitingUnresectable/Metastatic MelanomaCanada, Australia
-
Buzzard PharmaceuticalsBaylor Research InstituteRecruitingSolid Tumor, AdultUnited States
-
Beijing Friendship HospitalRecruitingLocally Advanced Rectal CancerChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingCarotid Artery Plaque | Pd-1 InhibitorsChina
-
Tongji HospitalWuhan University; Sun Yat-sen University; Wuhan Union Hospital, ChinaSuspendedNon Small Cell Lung CancerChina